Boxborough, MA, United States of America

Yaping Wang

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 11.6

ph-index = 4

Forward Citations = 84(Granted Patents)

Location History:

Cambridge, MA (US) (2012)
Boxborough, MA (US) (2008 - 2018)

Company Filing History:

Astex Therapeutics Limited

patents

where one patent can have more than one assignee

Years Active: 2008-2018

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10112931 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2018-10-30),

2. 9688672 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2017-06-27),

3. 9434719 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2016-09-06),

4. 9309252 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2016-04-12),

5. 8957074 - Pyrrolopyrimidine compounds as inhibitors of CDK4/6 (2015-02-17),

6. 8598217 - Imidazole derivatives and their use as modulators of cyclin dependent kinases (2013-12-03),

7. 8338440 - Inhibitors of IAP (2012-12-25),

8. 8207183 - Inhibitors of IAP (2012-06-26),

9. 7989441 - Organic compounds (2011-08-02),

10. 7419975 - Organic compounds (2008-09-02),

Title: Yaping Wang: Innovator in Pharmaceutical Chemistry

Introduction

Yaping Wang is a prominent inventor based in Boxborough, MA (US), known for his significant contributions to pharmaceutical chemistry. He holds a total of 10 patents, showcasing his innovative approach to drug development and disease treatment.

Latest Patents

One of Yaping Wang's latest patents involves the invention of 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH. This invention is directed to a specific formula, or a pharmaceutically acceptable salt thereof, wherein R, R, and R are defined within the patent. The invention also encompasses compositions containing this compound and its use in inhibiting mutant IDH proteins that exhibit neomorphic activity. Furthermore, it addresses the application of this compound in treating diseases or disorders associated with mutant IDH proteins, including cell-proliferation disorders such as cancer.

Career Highlights

Throughout his career, Yaping Wang has worked with notable companies in the pharmaceutical industry, including Novartis AG and Astex Therapeutics Limited. His experience in these organizations has contributed to his expertise in drug discovery and development.

Collaborations

Yaping Wang has collaborated with several professionals in his field, including Zhuoliang Chen and Fan Yang, who have contributed to his research and development efforts.

Conclusion

Yaping Wang's innovative work in pharmaceutical chemistry, particularly in the development of inhibitors for mutant IDH, highlights his significant impact on the field. His contributions continue to advance the understanding and treatment of critical diseases.

This text is generated by artificial intelligence and may not be accurate.